Limits...
HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients.

Yang J, Chen J, Ye P, Jin L, Wu W, Sheng G, Li LJ - J Transl Med (2014)

Bottom Line: Furthermore, the positive correlation between HBsAg and ALT, HBV DNA and Treg levels was significant for SC patients, but not for non-SC patients.However, for HBeAg, significant positive correlations were or not observed for both SC and non-SC patients.The quantitation of HBsAg is a more useful indicator than HBeAg for distinguishing SC and non-SC patients during TDF treatment.

View Article: PubMed Central - HTML - PubMed

Affiliation: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. ljli@zju.edu.cn.

ABSTRACT

Background: Serum quantitative hepatitis B surface antigen (HBsAg) levels may be an important predictor of hepatitis B e antigen (HBeAg) seroconversion (SC) in HBeAg-positive chronic hepatitis B (CHB) patients during antiviral treatment. The pattern of HBsAg variation in CHB patients either with or without SC following tenofovir disoproxil fumarate (TDF) treatment is not clearly understood.

Methods: Twenty patients with full experimental data were enrolled, and liver biochemistry, serum HBV DNA, and circulating CD4+CD25+ regulatory T cell (Treg) levels were determined at baseline and every 12 weeks after the initiation of TDF treatment (for a total of 96 weeks). In addition, the relationship between HBsAg or HBeAg and alanine aminotransferase (ALT), HBV DNA and Treg levels in SC and non-SC patients was analyzed.

Results: In all, 9 patients had undergone HBeAg seroconversion by week 72 of TDF treatment, and biochemical and virological indexes and Treg percentages declined to normal levels. Furthermore, the positive correlation between HBsAg and ALT, HBV DNA and Treg levels was significant for SC patients, but not for non-SC patients. However, for HBeAg, significant positive correlations were or not observed for both SC and non-SC patients.

Conclusions: The quantitation of HBsAg is a more useful indicator than HBeAg for distinguishing SC and non-SC patients during TDF treatment. Moreover, HBsAg may be related to immune regulatory property of CHB patients during antiviral treatment.

Show MeSH

Related in: MedlinePlus

Association between HBsAg or HBeAg and Treg frequencies in SC or non-SC patients during treatment. The relationship between serum HBsAg (log10 IU/ml) level and circulation CD4+CD25+ Treg frequency is shown for SC (A) and non-SC patients (B). The relationship between serum HBeAg (log10 S/CO) level and circulation CD4+CD25+ Treg frequency is shown for SC (C) and non-SC patients (D). Correlations were analyzed using Spearman correlation analysis.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4230803&req=5

Figure 4: Association between HBsAg or HBeAg and Treg frequencies in SC or non-SC patients during treatment. The relationship between serum HBsAg (log10 IU/ml) level and circulation CD4+CD25+ Treg frequency is shown for SC (A) and non-SC patients (B). The relationship between serum HBeAg (log10 S/CO) level and circulation CD4+CD25+ Treg frequency is shown for SC (C) and non-SC patients (D). Correlations were analyzed using Spearman correlation analysis.

Mentions: As was observed with the changing of serum HBsAg levels associated with HBV DNA loading, circulating Treg frequencies showed a very steady decline along with the HBsAg level decline in the SC group during TDF treatment, and there was a significant relationship between these two parameters (R = 0.900, P = 0.001; Figure 4A). However, in the non-SC group, the Treg frequency declined stably along with a fluctuant reduction in the HBsAg level during treatment, and the turning point for the declining HBsAg level was observed at week 12. In addition, there was no significance between HBsAg and HBV DNA loading (R = 0.611, P = 0.081; Figure 4B).


HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients.

Yang J, Chen J, Ye P, Jin L, Wu W, Sheng G, Li LJ - J Transl Med (2014)

Association between HBsAg or HBeAg and Treg frequencies in SC or non-SC patients during treatment. The relationship between serum HBsAg (log10 IU/ml) level and circulation CD4+CD25+ Treg frequency is shown for SC (A) and non-SC patients (B). The relationship between serum HBeAg (log10 S/CO) level and circulation CD4+CD25+ Treg frequency is shown for SC (C) and non-SC patients (D). Correlations were analyzed using Spearman correlation analysis.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4230803&req=5

Figure 4: Association between HBsAg or HBeAg and Treg frequencies in SC or non-SC patients during treatment. The relationship between serum HBsAg (log10 IU/ml) level and circulation CD4+CD25+ Treg frequency is shown for SC (A) and non-SC patients (B). The relationship between serum HBeAg (log10 S/CO) level and circulation CD4+CD25+ Treg frequency is shown for SC (C) and non-SC patients (D). Correlations were analyzed using Spearman correlation analysis.
Mentions: As was observed with the changing of serum HBsAg levels associated with HBV DNA loading, circulating Treg frequencies showed a very steady decline along with the HBsAg level decline in the SC group during TDF treatment, and there was a significant relationship between these two parameters (R = 0.900, P = 0.001; Figure 4A). However, in the non-SC group, the Treg frequency declined stably along with a fluctuant reduction in the HBsAg level during treatment, and the turning point for the declining HBsAg level was observed at week 12. In addition, there was no significance between HBsAg and HBV DNA loading (R = 0.611, P = 0.081; Figure 4B).

Bottom Line: Furthermore, the positive correlation between HBsAg and ALT, HBV DNA and Treg levels was significant for SC patients, but not for non-SC patients.However, for HBeAg, significant positive correlations were or not observed for both SC and non-SC patients.The quantitation of HBsAg is a more useful indicator than HBeAg for distinguishing SC and non-SC patients during TDF treatment.

View Article: PubMed Central - HTML - PubMed

Affiliation: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. ljli@zju.edu.cn.

ABSTRACT

Background: Serum quantitative hepatitis B surface antigen (HBsAg) levels may be an important predictor of hepatitis B e antigen (HBeAg) seroconversion (SC) in HBeAg-positive chronic hepatitis B (CHB) patients during antiviral treatment. The pattern of HBsAg variation in CHB patients either with or without SC following tenofovir disoproxil fumarate (TDF) treatment is not clearly understood.

Methods: Twenty patients with full experimental data were enrolled, and liver biochemistry, serum HBV DNA, and circulating CD4+CD25+ regulatory T cell (Treg) levels were determined at baseline and every 12 weeks after the initiation of TDF treatment (for a total of 96 weeks). In addition, the relationship between HBsAg or HBeAg and alanine aminotransferase (ALT), HBV DNA and Treg levels in SC and non-SC patients was analyzed.

Results: In all, 9 patients had undergone HBeAg seroconversion by week 72 of TDF treatment, and biochemical and virological indexes and Treg percentages declined to normal levels. Furthermore, the positive correlation between HBsAg and ALT, HBV DNA and Treg levels was significant for SC patients, but not for non-SC patients. However, for HBeAg, significant positive correlations were or not observed for both SC and non-SC patients.

Conclusions: The quantitation of HBsAg is a more useful indicator than HBeAg for distinguishing SC and non-SC patients during TDF treatment. Moreover, HBsAg may be related to immune regulatory property of CHB patients during antiviral treatment.

Show MeSH
Related in: MedlinePlus